BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37414978)

  • 21. ON THE ISSUE OF NECESSITY TO PERFORM THE DR-70 IMMUNOASSAY PRIOR TO PROSTATE BIOPSY IN PATIENTS WITH HIGH PROSTATE SPECIFIC ANTIGEN LEVEL AND ITS EFFICACY IN PREDICTING THE BIOPSY RESULTS.
    Ediz C; Akan S; Temel CM; Tavukcu HH; Yilmaz O
    Georgian Med News; 2019 Sep; (294):22-26. PubMed ID: 31687943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical research analysis based on prostate cancer screening diagnosis.
    Shan J; Geng X; Liu Z; Lu Y; Zhou R; Zhang Z; Xu H; Zhou X; Ma W; Zhu H; Shi H
    Andrologia; 2022 May; 54(4):e14371. PubMed ID: 35014705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml
    Wang C; Wang YY; Wang SY; Ding JX; Ding M; Ruan Y; Wang XH; Jing YF; Han BM; Xia SJ; Jiang CY; Zhao FJ
    Asian J Androl; 2021; 23(4):415-420. PubMed ID: 33473011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of the free to total prostate specific antigen ratio and prostate specific antigen density for detecting prostate cancer in Japanese patients.
    Maeda H; Arai Y; Okubo K; Aoki Y; Okada T; Maekawa S
    Int J Urol; 1998 Jul; 5(4):343-8. PubMed ID: 9712442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of prostate central gland/total gland volume ratio combined with PSA in the diagnosis of prostate cancer patients].
    Guo ZF; Lu XW; Yang F; Wu JW; Wang H; He C
    Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2836-2839. PubMed ID: 31550812
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml.
    Akdas A; Tarcan T; Türkeri L; Cevik I; Biren T; Ilker Y
    Eur Urol; 1996; 29(2):189-92. PubMed ID: 8647145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation.
    Klingler HC; Woo H; Rosario D; Cutinha PE; Anderson J; Ward AM; Chapple CR
    Br J Urol; 1998 Sep; 82(3):393-7. PubMed ID: 9772877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
    Naya Y; Fritsche HA; Cheli CD; Stamey TA; Bartsch G; Brawer MK; Childs S; Taneja SS; Lepor H; Partin AW; Sokoll LJ; Chan DW; Babaian RJ
    Urology; 2003 Dec; 62(6):1058-62. PubMed ID: 14665355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSA density as a better predictor of prostate cancer than percent-free PSA in a repeat biopsy.
    Chen CS; Wang SS; Li JR; Cheng CL; Yang CR; Chen WM; Ou YC; Ho HC; Chiu KY; Yang CK
    J Chin Med Assoc; 2011 Dec; 74(12):552-5. PubMed ID: 22196470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of free-to-total prostate specific antigen (F/T PSA), prostate specific antigen density (PSAD) and (F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone.
    Milkovic B; Dzamic Z; Pejcic T; Kajmakovic B; Nikolic D; Cirovic D; Knezevic T; Dzamic D; Hadzi-Djokic J
    Ann Ital Chir; 2014; 85(5):448-53. PubMed ID: 25599711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL.
    Zheng XY; Xie LP; Wang YY; Ding W; Yang K; Shen HF; Qin J; Bai Y; Chen ZD
    J Cancer Res Clin Oncol; 2008 Nov; 134(11):1207-10. PubMed ID: 18446367
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new model consists of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of prostate cancer.
    Xu D; Yu Y; Zhu Y; Huang T; Chen Y; Qi J
    Pathol Oncol Res; 2014 Apr; 20(2):439-43. PubMed ID: 24178678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
    Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
    [No Abstract]   [Full Text] [Related]  

  • 38. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
    Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
    Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
    Chen ZD; Wei SM; Cai SL
    Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.